Loading organizations...
§ Private Profile · New York City, NY, USA
venture capital firm investing in early-stage ophthalmic biotech and life sciences companies developing technologies and therapies.
ExSight Capital is a venture capital firm based in New York, United States, that invests in early-stage ophthalmic companies developing innovative technologies and therapies for the eye care industry. The organization manages three closed funds and currently has a fourth fund in the market, having recently announced the first close of ExSight Fund IV in January 2025. Its core investment strategy focuses heavily on biotechnology and life sciences within the ophthalmology sector, specifically targeting ocular pharmaceuticals, drug delivery systems, nanoparticle technology, and robotic surgery applications. The firm has invested in at least nine distinct portfolio companies to date, including recognizable names such as Re-Vana Therapeutics, 2C Tech, Horizon, and Elios Vision, which was acquired by Bausch + Lomb in 2024. ExSight Capital was officially founded in 2014 by co-founders James C. Murray, Firas M. Rahhal, and Michael Nissen.
Key people at ExSight Capital.
ExSight Ventures (also referred to as ExSight Capital) is a returns-oriented, mission-focused venture capital firm specializing in early-stage investments in innovative ophthalmic diagnostic and treatment solutions.[1][2][3] Its mission is to address the funding gap for life science companies developing breakthrough technologies in biotechnology, medical devices, pharmaceuticals, and software with ophthalmic applications, leveraging deep domain expertise from retinal surgeons to drive capital-efficient investments from pre-seed to Series B.[2][4] The firm's investment philosophy emphasizes specialization in ophthalmology to mitigate early-stage risks, provide operating support, and foster collaborations, differentiating it from generalist funds while targeting large populations affected by vision diseases.[2][3] In the startup ecosystem, ExSight impacts early-stage ophthalmic innovators by offering not just capital but insights from its surgeon-led team, enabling efficient technology development and value creation in a niche underserved by mega-funds.[2]
Founded in 2014 and based in New York, ExSight Ventures was established by accomplished retinal surgeons and investment professionals to bridge the dearth of early-stage funding for ophthalmic-focused life science companies.[2][5] Key partners include Founding Partner Adam Benowitz, Co-Founder and Partner James C. Murray, Partner Alan M. Spiro, and Partner Dr. Firas M. Rahhal, with additional team members like Maneesha Ghiya.[3][5] The firm's evolution centers on its founders' dual expertise in retinal surgery and venture capital/healthcare investing, allowing it to evolve from addressing a specific funding void into a specialized investor with a track record of over 20 deals across North America and Europe, including notable exits.[2][3] This operator-first approach has shaped its focus on disruptive ophthalmic innovations.[3]
ExSight rides the wave of specialized life sciences investing amid a dominance of mega-funds that often overlook niche early-stage opportunities in ophthalmology, a field critical for addressing vision diseases affecting millions.[2] Timing is favorable due to advances in biotech, AI-driven diagnostics, health tech, and medical devices, where domain-specific expertise de-risks high-potential innovations in a capital-constrained environment.[3] Market forces like rising demand for vision treatments, funding gaps in early life sciences, and the need for efficient capital allocation play to its strengths, particularly in the US and Canada.[3] By influencing the ecosystem through surgeon-led insights and collaborations, ExSight accelerates ophthalmic breakthroughs, fostering a more targeted startup pipeline that complements broader VC trends.[2][4]
ExSight Ventures is poised for expansion with its Dec 2024 fund in market, likely amplifying investments in AI-enhanced ophthalmic tools amid surging demand for precision vision therapies.[3][5] Trends like AI integration in health tech, personalized medicine, and post-pandemic biotech momentum will shape its trajectory, enabling more capital-efficient deals and exits.[3] Its influence may evolve by deepening operator networks and potentially scaling to adjacent eye care subsectors, solidifying its role as a go-to early-stage ophthalmic investor while staying true to its specialized, impact-driven roots.[2]
Key people at ExSight Capital.
